Navigation Links
Study Demonstrates Martek's Algal DHA Oil Improves Blood Triglyceride Lipid Levels
Date:9/4/2007

COLUMBIA, Md., Sept. 4 /PRNewswire-FirstCall/ -- Martek's life'sDHA(TM) from microalgae is effective in reducing the level of triglycerides in male hypertriglyceridemic patients, according to a study published in the current issue of The American Journal of Clinical Nutrition. In this study DHA (docosahexaenoic acid) alone was effective, without EPA (eicosapentaenoic acid), the other omega 3 commonly found in fish oil, in reducing triglycerides. Hypertriglyceridemia (high triglyceride levels) in men is associated with an increased risk of cardiovascular disease and metabolic syndrome.

The study, a randomized, parallel, double blind, placebo-controlled study that included 34 subjects, showed that supplementation with 3 grams DHA per day for 45 days resulted in a 24% decrease in fasting and postprandial triglyceride levels. This effect continued throughout the 90-day study period. Although LDL cholesterol increased by 13 percent, significant improvement was seen in the distribution of lipoprotein particle size. Researchers concluded that "DHA supplementation may improve cardiovascular health by lowering concentrations of triacylglycerols and small, dense LDL particles." The investigators used an EPA-free algal oil source of DHA, supplied by Martek. The study, authored by Dr. D. Kelly and associates, was conducted through the University of California Davis, Veterans Affairs of Northern California Health Care System and the US Department of Agriculture. Martek also contributed a portion of the funding for the study.

"The body of research supporting the health benefits of DHA for brain, eye and heart health throughout the lifecycle continues to grow," said Steve Dubin, CEO of Martek Biosciences.

Martek's life'sDHA(TM) is a vegetarian form of DHA omega-3, a long chain omega-3 fatty acid that serves as a primary building block for the brain and the eye and supports brain, eye and cardiovascular health throughout life. There is a large and growing body of scientific evidence demonstrating that people of all ages, from infants to aging adults, benefit from an adequate supply of DHA omega-3 in the diet. Scientific reviews have noted the importance of DHA omega-3 in proper brain and eye development and function, and there are clinical studies underway to evaluate its role in decreasing the prevalence of certain neurological disorders. Yet despite its importance, Americans have among the lowest dietary intakes of DHA omega-3 in the world.

Martek's life'sDHA(TM) is unique in the market because it is derived from a sustainable and vegetarian source. Made from microalgae under tightly controlled manufacturing conditions, life'sDHA(TM) is free of oceanic contaminants that may be present in certain fish or fish oils. Microalgae are the only vegetarian source of DHA omega-3, the key omega-3 for brain development and function.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit http://www.martek.com.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2006 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Contact:

Philip Fass

Public Relations

(443) 542-2570

pfass@martek.com

Kyle Stults

Investor Relations

(410) 740-0081

investors@martek.com


'/>"/>
SOURCE Martek
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Gene study links endometriosis, infertility
2. Study reveals how stress can make you sick
3. Study points out that HIV vaccine may not be accepted easily
4. A new study surpasses Gene Therapy Hurdle
5. Tomato Sauce reduces Cancer Risk- Study
6. A question on study of Adult Stem Cell
7. Study on obesity and heart failure
8. National Lung Study in the process
9. Marijuana gateway theory strengthened by study of twins
10. Old theory of adaptation confirmed by new study
11. Study casts doubt on keyboard ills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. Byrd, ... St. Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s conference was ... address the conference about her unique specialization in treating Lipedema. Dr. Byrd is considered ...
(Date:5/5/2016)... ... , ... Is the part in your hair widening? Are you finding more ... a good opportunity to raise awareness about a common condition among women: hair loss. ... women experience hair loss or ‘thinning’ by the time they reach menopause, but many ...
(Date:5/4/2016)... ... 04, 2016 , ... ProList is a set of 30 self-animating bullet points ... editors can easily create lists for presentations, youtube productions, and more. Simply choose ... is the perfect complement to presentation style videos. , ProList is a package of ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... and interview techniques, seeks to add a deeper understanding of the program, policy ... weaknesses, and each answers different yet important questions. , In a new brief ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Business Conference. The conference opened on Tuesday with Frank Luntz, sharing a dynamic, ... PDMP Solution provided a deep dive on NCPDP’s model solution to help stem ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
Breaking Medicine Technology: